Insulet Appoints Ana Maria Chadwick as CFO

Insulet Corporation (NASDAQ: PODD) has announced the appointment of Ana Maria Chadwick as the new Executive Vice President, Chief Financial Officer, and Treasurer effective April 22, 2024. Chadwick, an experienced public company CFO, will be joining Insulet from Pitney Bowes, where she currently serves as the Executive Vice President and CFO. With over 30 years of experience, Chadwick has been instrumental in the transformation of Pitney Bowes into a technology-enabled growth business.

During her tenure at Pitney Bowes, Chadwick played a crucial role in the company's transformation and has a proven track record of propelling growth for top-tier global organizations. Prior to her time at Pitney Bowes, she spent over 27 years at GE, holding various financial and operational roles.

Lauren Budden, who has been serving as the interim CFO and Treasurer, will continue in her role as Group Vice President, Chief Accounting Officer, and Controller.

Insulet Corporation, headquartered in Massachusetts, is dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod 5 automated insulin delivery system, which integrates with a continuous glucose monitor, is the company's flagship innovation and aims to manage blood sugar with zero fingersticks and no multiple daily injections.

Insulet Corporation is known for its tubeless insulin pump technology and its Omnipod insulin management system, which provides a unique alternative to traditional insulin delivery methods. With a simple, wearable design, the tubeless disposable pod offers up to three days of non-stop insulin delivery without the need to see or handle a needle.

The company has leveraged the design of its pod to tailor its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Today the company's shares have moved -2.8% to a price of $165.85. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.